Purdue Pharma and Actavis Settle Oxycontin Patent Lawsuit

Submitted by patentadmin on Thu, 05/02/2013 - 12:05

May 2, 2013 - Purdue Pharma and Actavis, Inc. have resolved the patent infringement litigation that was pending between the two companies in a district court in New York.

The litigation began when Purdue sued Actavis for infringing patents that cover OxyContin, including a reformulated version of OxyContin that is abuse-deterrent because it has “physical and chemical properties that are expected to make abuse via injection difficult and to reduce abuse via the intranasal route.”

Under the agreement, Actavis will acknowledge the validity and enforceability of the Purdue patents and that its generic version of OxyContin infringed those patents. Actavis will also take a license from Purdue to sell predefined quantities of a generic version of the reformulated OxyContin as early as 2014.